| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023943 A cephem compound (particularly its crystal) represented by the formula (I), wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such |
| 02/05/2004 | US20040023942 Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
| 02/05/2004 | US20040023941 Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and |
| 02/05/2004 | US20040023937 Anti-cancer formulation |
| 02/05/2004 | US20040023936 17 Beta-amino and hydroxylamino-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 02/05/2004 | US20040023935 Inhalation compositions, methods of use thereof, and process for preparation of same |
| 02/05/2004 | US20040023934 Method of treating prostatic diseases using active vitamin D analogues |
| 02/05/2004 | US20040023933 Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-Xt-L-(W)p-NO2 wherein A contains the radical of a drug, Xt and W arc bivalent radicals, L, is a |
| 02/05/2004 | US20040023932 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the |
| 02/05/2004 | US20040023931 Method for maintaining a healthy bone structure by administering to a patient a bone health promoting effective amount of a medicament containing 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic |
| 02/05/2004 | US20040023930 Active ingredient combination having insecticidal and acaricidal characteristics |
| 02/05/2004 | US20040023928 The present invention provides methods of treating smallpox and other poxvirus infections with a pharmaceutically effective amount of LY582563 or LY217896. |
| 02/05/2004 | US20040023927 Bicyclic imidazo-5-yl-amine derivatives |
| 02/05/2004 | US20040023925 Method for enhancing the effectiveness of therapies of hyperproliferative diseases |
| 02/05/2004 | US20040023923 Beta -Glucan which is cold-water soluble and is capable of forming a gel. The solubility is greater than 2% by weight in water at a temperature below approximately 50 degrees C. A process for preparing the beta -glucan by recovering the |
| 02/05/2004 | US20040023922 Lipids for modulating immune response |
| 02/05/2004 | US20040023921 Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase. |
| 02/05/2004 | US20040023920 The use of adenosine-5'-triphosphate-2',3'-dialdehyde (oATP) as a medicament useful for the treatment of inflammatory conditions |
| 02/05/2004 | US20040023919 Atorvastatin in combination with one or more members selected from a riboflavin derivative, a tocopherol compound, an ascorbic acid derivative, pantethine and taurine. |
| 02/05/2004 | US20040023917 Treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins. |
| 02/05/2004 | US20040023916 Key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK also antagonizes TNAP-dependent matrix |
| 02/05/2004 | US20040023909 Process for preventing or reducing undesirable immunological effects to infectious agents in subjects |
| 02/05/2004 | US20040023901 Novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a |
| 02/05/2004 | US20040023900 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/05/2004 | US20040023899 Extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water |
| 02/05/2004 | US20040023898 Single dose azithromycin |
| 02/05/2004 | US20040023897 Methods for preventing or treating disease mediated by toxin-secreting bacteria |
| 02/05/2004 | US20040023896 Compounds as antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to drugs for bacterial protozoa infections by administering the compounds of formula 1. |
| 02/05/2004 | US20040023894 Synergistic antioxidant combination of delta tocols and polyphenols |
| 02/05/2004 | US20040023893 Coumarin derivatives for treatment of vascular disorders, skin disorders or allergies |
| 02/05/2004 | US20040023892 Pharmaceutical composition based on a non-steroid anti-inflammatory agent |
| 02/05/2004 | US20040023891 Agents for neutron capture therapy |
| 02/05/2004 | US20040023890 Drugs for diabetes |
| 02/05/2004 | US20040023885 Islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided |
| 02/05/2004 | US20040023881 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023867 Methods and compositions for treating benign gynecological disorders |
| 02/05/2004 | US20040023857 Treatment of rosacea |
| 02/05/2004 | US20040023852 Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG |
| 02/05/2004 | US20040023848 Non-absorbable compositions that bind specifically to target microorganisms in a patient's gastrointestinal tract to remove them, without affecting the normal flora, to prevent both gastrointestinal illness and drug resistance of said microbes |
| 02/05/2004 | US20040023847 (5-(2-Hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 02/05/2004 | US20040023844 Method and device for controlling drug pharmacokinetics |
| 02/05/2004 | US20040023843 Treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an |
| 02/05/2004 | US20040023840 Combination of organic compounds |
| 02/05/2004 | US20040023386 Modulation of nitric oxide synthase by PKC |
| 02/05/2004 | US20040023335 IL-17 like molecules and uses thereof |
| 02/05/2004 | US20040023299 Diagnosis of liver disease |
| 02/05/2004 | US20040023290 Novel therapeutic agents that modulate enzymatic processes |
| 02/05/2004 | US20040023240 Combinatorial production of nucleotide and nucleoside(xitp)analogues |
| 02/05/2004 | US20040023207 Assays for screening compounds based on their effectiveness in modulating such microcompetition; effective compounds can be used in treatment of these chronic diseases |
| 02/05/2004 | US20040022922 Infant formula supplemented with phospholipids |
| 02/05/2004 | US20040022881 Antioxidant food and beverage supplements |
| 02/05/2004 | US20040022879 Platelet Activating Factor Inhibitor and an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity; especially useful for treating asthma in children. |
| 02/05/2004 | US20040022878 Alkylamides content lower than 0.1%, an echinacoside content of 1-10% and a polysaccharide content of 1-15%, the polysaccharide weighing 1.3 x 105 Da and consisting of rhamnose, arabinose, galactose and galacturonic acid |
| 02/05/2004 | US20040022873 Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses |
| 02/05/2004 | US20040022871 Halogenated composition, method for preparing same and uses thereof |
| 02/05/2004 | US20040022869 Containing microtubule stabilizing agents and one or more heat shock protein (HSP)-inducing agents; treating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder |
| 02/05/2004 | US20040022867 Neutralizes the adverse health effects of both chemical and biological compounds, especially chemical and biological warfare agents, and toxic industrial chemicals; includes solubilizers and oxididative detoxifiers |
| 02/05/2004 | US20040022866 Use of sodium and potassium salts of citric, phosphoric, carbonic and tartaric acid and arginine and lysine as stabilizer of the antibiotic Fosfomycin Tromethamine |
| 02/05/2004 | US20040022863 Boric Acid, Zinc oxide, Calamine, Cetrimide, Olive Oil, Castor Oil, Cod liver Oil, White Petroleum base, Salicylic Acid, and Tannic Acid |
| 02/05/2004 | US20040022862 Precipitating organic compounds in an aqueous medium to form a pre-suspension followed by adding energy to stabilize a coating of the particle or to alter its lattice structure |
| 02/05/2004 | US20040022856 Carriers for drug delivery |
| 02/05/2004 | US20040022855 Cored tablets comprising amoxicillin and clavulanate |
| 02/05/2004 | US20040022854 Oral administration of proton pump inhibitor |
| 02/05/2004 | US20040022853 Polymer-based, sustained release drug delivery system |
| 02/05/2004 | US20040022852 Chemical delivery device |
| 02/05/2004 | US20040022851 Sustained release of guaifenesin combination drugs |
| 02/05/2004 | US20040022850 Modified release formulation |
| 02/05/2004 | US20040022849 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 02/05/2004 | US20040022847 Delivering by oral ingestion a nutritional supplement consisting of an hyaluronic acid, or a salt or digest thereof, and a food acceptable carrier for relieving joint pain or other discomforts associated with joint disorders |
| 02/05/2004 | US20040022846 Reduced side-effects |
| 02/05/2004 | US20040022845 Oral formulations for localized colonic release and the method of preparation thereof |
| 02/05/2004 | US20040022844 Using as carriers of pharmaceutical active constituents and/or auxiliary substances |
| 02/05/2004 | US20040022843 Lipophilic electrophoretic probes |
| 02/05/2004 | US20040022842 Liposome preparations containing oxaliplatin |
| 02/05/2004 | US20040022841 Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof |
| 02/05/2004 | US20040022837 Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
| 02/05/2004 | US20040022836 Transdermal therapeutic systems comprising photosensitive active substances |
| 02/05/2004 | US20040022835 Transdermal composition of an antivomiting agent |
| 02/05/2004 | US20040022834 Pharmaceutical oxan preparation |
| 02/05/2004 | US20040022831 For therapy of mycosis of the nail |
| 02/05/2004 | US20040022829 Methods for treating, maintaining, or improving fur or hair pigmentation of domestic carnivores using a composition comprising free tyrosine |
| 02/05/2004 | US20040022827 Administering to a subject in need thereof, who has not been hepatectomized, an effective amount of valine as an active ingredient free of other amino acids |
| 02/05/2004 | US20040022820 To solubilize pharmaceutical actives difficult for the body to absorb |
| 02/05/2004 | US20040022817 Non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered |
| 02/05/2004 | US20040022816 Fluid for haemofiltration |
| 02/05/2004 | US20040022815 Novel pharmaceutical composition of ceftiofur |
| 02/05/2004 | US20040022801 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2004 | US20040022793 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 02/05/2004 | US20040022789 Methods and compositions for treating T cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency |
| 02/05/2004 | US20040022778 For therapy and prophylaxis of cardiovascular disease, strokes and myocardial infarction |
| 02/05/2004 | US20040022768 Process useful for producing selective immune down regulation (SIDR) in subjects, including adult subjects to artificially expressed gene, gene delivery systems, infectious agents, and non-cellular immunogenic components, and processes for producing immunological tolerance in subjets using SIDR |
| 02/05/2004 | US20040022766 Administering by subretinal injection an effective amount of recombinant adeno-associated virus carrying a nucleic acid sequence encoding normal gene under the control of promoter sequence which expresses the product of gene in ocular cells |
| 02/05/2004 | US20040022764 Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
| 02/05/2004 | US20040022762 Use of il-8 protein modulators in the treatment of viral infections |
| 02/05/2004 | US20040022761 Compositions and methods for producing antigen-presenting cells |
| 02/05/2004 | US20040022759 Ionic polymers as anti-infective agents |
| 02/05/2004 | US20040022758 Hair tonics and method of screening the same |
| 02/05/2004 | US20040022756 1,2-propylene glycol skin preparation solution and method of use thereof |